US Stock MarketDetailed Quotes
EYPT EyePoint Pharmaceuticals
- 12.060
- +0.300+2.55%
Close Nov 1 16:00 ET
- 12.060
- 0.0000.00%
Post 20:02 ET
821.94MMarket Cap-6775P/E (TTM)
12.470High11.310Low839.28KVolume11.880Open11.760Pre Close9.99MTurnover1.66%Turnover RatioLossP/E (Static)68.15MShares30.99052wk High3.60P/B608.93MFloat Cap5.85552wk Low--Dividend TTM50.49MShs Float72.200Historical High--Div YieldTTM9.86%Amplitude2.190Historical Low11.903Avg Price1Lot Size
EyePoint Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 4.09%9.48M | 52.08%11.68M | 11.14%46.02M | 33.18%14.03M | 51.84%15.2M | -21.27%9.11M | -17.33%7.68M | 12.09%41.4M | -8.76%10.53M | 10.52%10.01M |
| Operating revenue | 4.09%9.48M | 52.08%11.68M | 11.14%46.02M | 33.18%14.03M | 51.84%15.2M | -21.27%9.11M | -17.33%7.68M | 12.09%41.4M | -8.76%10.53M | 10.52%10.01M |
| Cost of revenue | -21.82%1.4M | 18.59%759K | -44.37%4.63M | -70.73%998K | -14.45%1.2M | 3.34%1.79M | -63.98%640K | 1.82%8.33M | 12.43%3.41M | -23.01%1.41M |
| Gross profit | 10.43%8.08M | 55.12%10.93M | 25.12%41.39M | 82.93%13.03M | 62.66%14M | -25.61%7.31M | -6.31%7.04M | 15.01%33.08M | -16.31%7.12M | 18.98%8.61M |
| Operating expense | 41.72%42.62M | 54.72%44.25M | 3.96%116.45M | -2.57%29.38M | 5.16%28.4M | 3.54%30.07M | 10.84%28.6M | 33.29%112.02M | 13.55%30.16M | 19.77%27.01M |
| Selling and administrative expenses | -10.76%12.8M | -5.82%14.11M | -14.15%51.79M | -20.66%11.43M | -27.53%11.04M | -7.10%14.34M | -1.72%14.98M | 13.65%60.32M | -15.37%14.41M | 13.35%15.23M |
| -Selling and marketing expense | -99.05%50K | -99.90%6K | -54.17%11.69M | -96.87%185K | -92.04%479K | -23.17%5.29M | -14.28%5.74M | -7.26%25.51M | -24.27%5.92M | -18.42%6.02M |
| -General and administrative expense | 40.79%12.75M | 52.58%14.1M | 15.18%40.1M | 32.39%11.25M | 14.59%10.56M | 5.83%9.06M | 8.12%9.24M | 36.14%34.82M | -7.82%8.5M | 52.01%9.21M |
| Research and development costs | 89.59%29.82M | 121.32%30.14M | 30.26%64.66M | 15.49%17.95M | 55.55%17.36M | 21.07%15.73M | 36.93%13.62M | 74.18%49.64M | 74.29%15.54M | 31.35%11.16M |
| Depreciation amortization depletion | ---- | ---- | --0 | --0 | --0 | ---- | ---- | -16.67%2.05M | -66.67%205K | 0.00%615K |
| -Depreciation and amortization | ---- | ---- | --0 | --0 | --0 | ---- | ---- | -16.67%2.05M | -66.67%205K | 0.00%615K |
| Operating profit | -51.78%-34.55M | -54.59%-33.32M | 4.90%-75.07M | 29.01%-16.35M | 21.74%-14.4M | -18.45%-22.76M | -17.88%-21.55M | -42.81%-78.94M | -27.62%-23.04M | -20.15%-18.4M |
| Net non-operating interest income expense | 213.13%3.72M | 935.13%4.04M | 638.94%5.7M | 726.15%2.34M | 8,218.18%1.79M | 725.26%1.19M | 134.42%390K | 79.68%-1.06M | 120.48%283K | 98.41%-22K |
| Non-operating interest income | 129.21%3.72M | 235.86%4.04M | 226.09%6.95M | 119.74%2.34M | 179.06%1.79M | 348.34%1.62M | 1,870.49%1.2M | 629.79%2.13M | 17,633.33%1.06M | 10,566.67%640K |
| Non-operating interest expense | --0 | --0 | -60.90%1.25M | --0 | --0 | -21.20%435K | -31.99%812K | -42.00%3.19M | -43.73%781K | -52.31%662K |
| Other net income (expense) | 93.95%-1.35M | 0 | -1.35M | -1,177.87%-22.26M | -20.7M | |||||
| Special income (charges) | --0 | ---- | 93.95%-1.35M | --0 | --0 | ---1.35M | ---- | -1,177.87%-22.26M | ---20.7M | --0 |
| -Less:Impairment of capital assets | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --20.7M | ---- | ---- |
| -Less:Other special charges | ---- | ---- | -13.60%1.35M | --0 | ---- | --1.35M | ---- | 175.50%1.56M | --0 | ---- |
| Income before tax | -34.49%-30.83M | -38.37%-29.28M | 30.85%-70.71M | 67.74%-14.02M | 31.53%-12.61M | -18.11%-22.92M | -0.90%-21.16M | -75.04%-102.25M | -123.61%-43.45M | -10.33%-18.42M |
| Income tax | 83K | 0 | ||||||||
| Net income | -34.49%-30.83M | -38.37%-29.28M | 30.77%-70.8M | 67.55%-14.1M | 31.53%-12.61M | -18.11%-22.92M | -0.90%-21.16M | -75.04%-102.25M | -123.61%-43.45M | -10.33%-18.42M |
| Net income continuous Operations | -34.49%-30.83M | -38.37%-29.28M | 30.77%-70.8M | 67.55%-14.1M | 31.53%-12.61M | -18.11%-22.92M | -0.90%-21.16M | -75.04%-102.25M | -123.61%-43.45M | -10.33%-18.42M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -34.49%-30.83M | -38.37%-29.28M | 30.77%-70.8M | 67.55%-14.1M | 31.53%-12.61M | -18.11%-22.92M | -0.90%-21.16M | -75.04%-102.25M | -123.61%-43.45M | -10.33%-18.42M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -34.49%-30.83M | -38.37%-29.28M | 30.77%-70.8M | 67.55%-14.1M | 31.53%-12.61M | -18.11%-22.92M | -0.90%-21.16M | -75.04%-102.25M | -123.61%-43.45M | -10.33%-18.42M |
| Basic earnings per share | 4.92%-0.58 | 1.79%-0.55 | 33.58%-1.82 | 72.41%-0.32 | 32.65%-0.33 | -17.31%-0.61 | 0.00%-0.56 | -34.98%-2.74 | -96.61%-1.16 | 15.52%-0.49 |
| Diluted earnings per share | 4.92%-0.58 | 1.79%-0.55 | 33.58%-1.82 | 72.41%-0.32 | 32.65%-0.33 | -17.31%-0.61 | 0.00%-0.56 | -34.98%-2.74 | -96.61%-1.16 | 15.52%-0.49 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data